** Shares of drug developer Relmada Therapeutics rise 4.9% to 48 cents
** Co says it has commenced a process to explore strategic alternatives after discontinuing two late-stage studies planned for the development of its depression drug
** Co plans to consider a wide range of options including sale of company assets, a sale of the company, a merger or a reverse merger; adds it has not set a timetable for completion of the evaluation process
** Says co is in the process of engaging a financial advisor to assist in the strategic review process
** The stock fell more than 70% last week after the company said its depression drug, esmethadone, was "unlikely" to meet the main goal of a late-stage trial
** Including session moves, stock down 88.4% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。